PF-Atlas › Clinical Trials › NCT05274269

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects Without an F508del Mutation

ELX/TEZ/IVA · Phase 3

Registry ID
NCT05274269
Phase
Phase 3
Status
Completed
Drug / intervention
ELX/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2022-05-09
Enrollment
307
Locations
90

About this trial

This study evaluated the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.

View NCT05274269 on ClinicalTrials.gov →

Explore related

All ELX/TEZ/IVA trialsAll IPF trials

Related trials

ELX/TEZ/IVA — NCT05153317ELX/TEZ/IVA — NCT04545515ELX/TEZ/IVA — NCT03691779ELX/TEZ/IVA — NCT04702360ELX/TEZ/IVA — NCT04362761ELX/TEZ/IVA — NCT04105972
Medical disclaimer. This page summarizes public trial data for NCT05274269 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.